Qi Zhang

University of Western Ontario
Country flagCanada

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (15)

Year:

2026

Year:

2026

Year:

2026

Background: Fall from height is common in all age groups. In 2020 alone, over 6000 people in Canada died from fall-related injuries. Most of the published literature investigating fall-related injuries are often focused on fracture patterns, survival and recovery. Fatal falls are not well studied. The objective of this study is to characterize the demographics and craniocerebral and vertebrospinal injury patterns related to fatal falls within Southwestern Ontario. Methods: A retrospective case review was conducted at the Department of Pathology, London Health Sciences Centre, for deaths attributed to falls from 2000 to 2020. Only cases with complete autopsy and detailed neuropathology reports were included. Demographic data, comorbidity profiles and craniocerebral and vertebrospinal injuries, along with scene details, were collected and analyzed. Results: 45 cases were included, with a male sex predominance and a mean age of 60.3 ± 18.1 years. The most common head injuries were hematoma, cerebral contusions and skull base fractures. Falls from stairs were the most common. Low fall ( 65 years). Younger individuals were more prone to falls from a high height (>3 m), with frontotemporal lobe contusions as the most common finding. Discussion: This study provides a detailed depiction of craniocerebral and vertebrospinal injury patterns of the fatal falls in Southwestern Ontario. Our findings show low falls are a more common cause of fatalities in individuals 65 years and older, and age is a significant predictor of frontal contusions and subdural hematomas.

Year:

2026

Year:

2026

Year:

2026

Brain metastasis occurs in up to 40% of patients with non–small cell lung cancer (NSCLC). Considerable genomic heterogeneity exists between the primary lung tumor and respective brain metastasis; however, the identity of the genes capable of driving brain metastasis is incompletely understood. Here, we carried out an in vivo genome-wide CRISPR activation screen to identify molecular drivers of brain metastasis from an orthotopic xenograft model derived from a patient with NSCLC. We found that activating expression of the Alzheimer’s disease–associated beta-secretase 1 (BACE1) led to a substantial increase in brain metastases. Furthermore, genetic and pharmacological inhibition of BACE1 blocked NSCLC brain metastasis. Mechanistically, we identified that BACE1 acts through epidermal growth factor receptor to drive this metastatic phenotype. Together, our data highlight the power of in vivo CRISPR activation screening to unveil molecular drivers and potential therapeutic targets of NSCLC brain metastasis.

Year:

2025

Aims Accurately and efficiently identifying mitotic figures (MFs) is crucial for diagnosing and grading various cancers, including glioblastoma (GBM), a highly aggressive brain tumour requiring precise and timely intervention. Traditional manual counting of MFs in whole slide images (WSIs) is labour‐intensive and prone to interobserver variability. Our study introduces a deep active learning framework that addresses these challenges with minimal human intervention. Methods and results We utilized a dataset of GBM WSIs from The Cancer Genome Atlas (TCGA). Our framework integrates convolutional neural networks (CNNs) with an active learning strategy. Initially, a CNN is trained on a small, annotated dataset. The framework then identifies uncertain samples from the unlabelled data pool, which are subsequently reviewed by experts. These ambiguous cases are verified and used for model retraining. This iterative process continues until the model achieves satisfactory performance. Our approach achieved 81.75% precision and 82.48% recall for MF detection. For MF subclass classification, it attained an accuracy of 84.1%. Furthermore, this approach significantly reduced annotation time ‐ approximately 900 min across 66 WSIs ‐ cutting the effort nearly in half compared to traditional methods. Conclusions Our deep active learning framework demonstrates a substantial improvement in both efficiency and accuracy for MF detection and classification in GBM WSIs. By reducing reliance on large annotated datasets, it minimizes manual effort while maintaining high performance. This methodology can be generalized to other medical imaging tasks, supporting broader applications in the healthcare domain.

Year:

2025

Pediatric central nervous system (CNS) tumors are often classified by distinct histologic and molecular features; however, some tumors remain unclassified, resulting in diagnostic and therapeutic challenges. We report a case of a previously healthy 3-year-old female who presented with right eyelid ptosis and headache. Imaging revealed a right middle cranial fossa mass. Following surgery and histopathologic and molecular analyses, the diagnosis was a malignant neoplasm with mixed neural and myoblastic differentiation, not elsewhere classified based on the current World Health Organization (WHO) classification. We describe a unique hybrid treatment approach for this rare tumor consisting of rhabdomyosarcoma and embryonal treatment regimens.

Year:

2025

BACKGROUND Breast cancer brain metastases (BCBMs) are a feared complication of breast cancer and associated with a poor prognosis. The molecular and biological events that give rise to BCBMs are not fully understood. The project aims are to characterize the clinicopathological outcomes of patients who underwent surgical resection or biopsy of BCBMs at London Health Sciences Centre (LHSC) and further compare the biomarker profiles between primary tumor and BM. MATERIAL AND METHODS Patients who had BCBMs surgically-resected or biopsied at LHSC were identified. Retrospective chart review was conducted to collect patients demographics, details on primary BC and BM diagnoses and treatments, pathology details, and clinical outcomes. Kaplan-Meier curves were generated and uni- and multivariate Cox-regression analyses were conducted to determine clinical outcome predictors. RESULTS Seventy-five female patients were identified. Mean age at BCBM diagnosis was 56.1 years and mean time to developing BCBM was 5.4 years (range: 0-23.0 years). Triple-negative (18/75, 24.0%) and HER2+ (14/75, 18.7%) were the most common subtypes. Median overall survival (OS) after BCBM diagnoses was 2.4 years. Solitary BCBM (p=0.0276) and no extracranial systemic disease (p=0.0276) were associated with longer OS after BCBM diagnosis. 51 patients had paired immunohistochemistry (IHC) markers of their primary BC and BMs. 12/51 (23.5%) patients exhibited a subtype switch with hormone receptor loss (5/12, 41.7%) being the most common change. Univariate Cox-regression analyses for these 51 patients demonstrated that triple-negative subtype (HR 2.81, p=0.0075), multiple BMs (HR 3.23, p=0.0024), neurological deficits (HR 3.06, p=0.0058), tumor >3 cm (HR 2.84, p=0.013), and hydrocephalus (HR 4.13, p=0.014) were negative prognostic factors. After multivariate Cox-regression, only triple-negative subtype (3.52, p=0.0033) and multiple BMs (2.34, p=0.047) remained significant. Subtype switching did not appear to impact OS (p=0.27). CONCLUSION The management of BCBM remains challenging with overall survival remaining poor, especially in those with triple-negative disease, multiple BMs, and widespread metastatic disease. Within our cohort, a noticeable proportion of patients exhibited biomarker profile shifting between the primary BC and BCBM. This may have clinical implications and further investigations are required.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Collaborators (25)

Jongmyung Kim

Assistant Professor

University of South Florida

UNITED STATES
View details

Sheila K. Singh

McMaster University

CANADA
View details

Charles Swanton

Chief Clinician

-

UNITED KINGDOM
View details

Boyu Wang

Assistant Professor

Western University

CANADA
View details

Michael Kovacs

University of Western Ontario

CANADA
View details

Shawn N. Whitehead

Western University

CANADA
View details

Chantel Cacciotti

Western University

CANADA
View details

Sandrine de Ribaupierre

Western University

CANADA
View details

Jason Moffat

Senior Scientist and Program Head

Hospital for Sick Children

CANADA
View details

Ariana Huebner

University College London

UNITED KINGDOM
View details

Jian‐Qiang Lu

Neuropathologist

McMaster University Faculty of Health Sciences

CANADA
View details

Adrian Budhram

-

CANADA
View details

Blessing Bassey-Archibong

Assistant Professor

Concordia University of Edmonton

CANADA
View details

Lena Palaniyappan

Chair

McGill University

CANADA
View details

Kui Zhai

McMaster University

CANADA
View details

Shawn Li

Professor

Western University

CANADA
View details

Teneille Gofton

Assistant Professor

Western University

CANADA
View details

Christina Castellani

Western University

CANADA
View details

Antoine Dufour

Professor

University of Calgary

CANADA
View details

James K. C. Liu

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Shawn Chafe

Research Associate

McMaster University

CANADA
View details

Justin Hicks

Assistant Professor

Western University

CANADA
View details

David Plemel

Western University

CANADA
View details

Stephen Pasternak

Scientist, Associate Professor

Western University

CANADA
View details

David Driman

Chair

Western University

CANADA
View details